Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A novel monocyte-based biomarker of cardiovascular risk: comparison with traditional cardiovascular risk calculators.

American journal of preventive cardiology·2026
Same author

Versatile 1,2,3-Triazole Hybrids in Breast Cancer Treatment: From Molecular Mechanisms to Therapeutic Promise.

Current medicinal chemistry·2026
Same author

Clinical and economic burden of recurrence among older patients with locoregionally advanced head and neck squamous cell carcinoma in the United States.

Journal of managed care & specialty pharmacy·2026
Same author

Genome-wide characterization of LPMOs and CAZymes in camel rumen-derived Paenibacillus barengoltzii highlights strong lignocellulolytic potential.

BMC microbiology·2026
Same author

Efficacy of upadacitinib induction for pediatric inflammatory bowel disease.

JPGN reports·2026
Same author

Integrated in vitro and in silico evaluation of rutin as a potential modulator of wound healing pathways.

Molecular diversity·2026

Related Experiment Video

Updated: Mar 22, 2026

Stereotactic Radiosurgery for Gynecologic Cancer
10:35

Stereotactic Radiosurgery for Gynecologic Cancer

Published on: April 17, 2012

18.8K

Stereotactic Radiosurgery for Poor Performance Status Patients.

Gregory J Kubicek1, Alan Turtz2, Jinyu Xue1

  • 1Department of Radiation Oncology, Cooper University Hospital, Camden, New Jersey.

International Journal of Radiation Oncology, Biology, Physics
|April 27, 2016
PubMed
Summary

Stereotactic radiosurgery (SRS) offers a viable treatment for patients with poor performance status (PS) and central nervous system (CNS) metastases, demonstrating reasonable survival and low failure rates. This approach may be preferable to whole-brain radiation therapy (WBRT) for select patients.

More Related Videos

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy
08:54

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Published on: May 8, 2018

15.1K
Dynamic Lung Tumor Tracking for Stereotactic Ablative Body Radiation Therapy
08:17

Dynamic Lung Tumor Tracking for Stereotactic Ablative Body Radiation Therapy

Published on: June 7, 2015

16.3K

Related Experiment Videos

Last Updated: Mar 22, 2026

Stereotactic Radiosurgery for Gynecologic Cancer
10:35

Stereotactic Radiosurgery for Gynecologic Cancer

Published on: April 17, 2012

18.8K
Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy
08:54

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Published on: May 8, 2018

15.1K
Dynamic Lung Tumor Tracking for Stereotactic Ablative Body Radiation Therapy
08:17

Dynamic Lung Tumor Tracking for Stereotactic Ablative Body Radiation Therapy

Published on: June 7, 2015

16.3K

Area of Science:

  • Neuro-oncology
  • Radiation Oncology
  • Clinical Outcomes Research

Background:

  • Patients with poor performance status (PS), defined as Karnofsky Performance Status ≤60, are often excluded from stereotactic radiosurgery (SRS) trials.
  • Current guidelines frequently recommend whole-brain radiation therapy (WBRT) as the primary treatment for this patient group.
  • Limited data exists on the efficacy and safety of SRS in patients with poor PS and central nervous system (CNS) metastases.

Purpose of the Study:

  • To evaluate the outcomes of stereotactic radiosurgery (SRS) in patients with poor performance status (PS) and central nervous system (CNS) metastatic disease.
  • To compare SRS outcomes in this population with historical data or expectations for whole-brain radiation therapy (WBRT).

Main Methods:

  • Retrospective review of a stereotactic radiosurgery (SRS) database.
  • Inclusion of 36 patients with Karnofsky Performance Status (KPS) of 60 or less treated with SRS for CNS metastases.
  • Analysis of overall survival (OS), local and distant failure rates, and treatment toxicity.

Main Results:

  • Median overall survival (OS) was 7.2 months; 41% survived at 6 months and 16.6% at 1 year.
  • No significant difference in OS was observed in patients with prior WBRT.
  • No local failures or radiation toxicity were reported; distant CNS failures occurred in 25% of patients.

Conclusions:

  • Patients with poor performance status (PS) treated with SRS for CNS metastases demonstrated reasonable median OS and low distant CNS failure rates.
  • SRS may be a favorable alternative to WBRT for poor PS patients due to low failure rates and convenient single-fraction treatment.
  • The findings suggest SRS is a safe and effective option for select debilitated patients with CNS metastases.